SibMed scientists conduct the world's first study to predict colon cancer
09.09.2024
The research results of SibMed scientists will help predict the clinical course of colorectal cancer and open up prospects for the development of new drugs.
Colon cancer is the most common tumor of the gastrointestinal tract. In terms of mortality, the disease ranks second only to malignant neoplasms of the breast and lungs. The risk of developing colorectal cancer increases with age. People over the age of 50 are at risk.
The disease is difficult to detect early and conventional treatment is often ineffective. Therefore, researchers are actively seeking additional molecular and cellular markers of the progression of the disease. These markers may include the proteins galectin-1 and galectin-3. They are involved in almost all stages of tumor development and progression, including the mechanisms of malignant cell transformation, tumor development and metastasis.
To expand SibMed research capabilities, a Molecular Medicine Laboratory will be established as part of the strategic project "Precision Medicine" of the Priority 2030 program. In addition to exploring methods to predict the course of colon cancer, the research team will search for biomarkers of damage and study regeneration mechanisms in diseases associated with inflammation and vascular pathology. These include ischemic cardiomyopathy, diabetes mellitus, rheumatic diseases and pathologies associated with soft tissue dysangiogenesis.
